In the labyrinth of human biology, some of the most surprising discoveries emerge from the smallest players. A new study from Tufts University School of Medicine and the Tufts Graduate School of Biomedical Sciences sheds light on a novel connection between the gut–brain axis — specifically, how a common gut fungus, Candida albicans, may influence our relationship with alcohol.

Published on October 16 in the journal mBio, the study explores how this seemingly benign fungus, when overgrown in the gut, can disrupt the brain’s dopamine reward system — potentially altering behavior related to alcohol consumption. The research was conducted in mice, but its implications open the door to new understandings of Alcohol Use Disorder (AUD), a condition affecting over 5% of adults globally.

A Fungus with Unexpected Influence

Candida albicans is a normal resident of the human gut microbiome, usually kept in check by other microbes and a healthy immune system. However, under certain conditions — like poor diet, antibiotic use, or frequent alcohol consumption — it can overgrow, triggering a cascade of effects.

The researchers focused on the role of PGE₂ (prostaglandin E₂), a multifunctional molecule involved in inflammation, fever, and digestive regulation. As C. albicans blooms in the gut, it stimulates the production of PGE₂, which is capable of crossing the blood–brain barrier (BBB).

Crossing from Gut to Brain

Once in the brain, PGE₂ molecules appear to alter dopamine signaling in the dorsal striatum, a region associated with reward, motivation, and habit formation. Dopamine is a key neurotransmitter in addiction science — it’s the chemical that makes us feel good when we eat chocolate, win a game, or, in many cases, drink alcohol.

Dopamine Pathways. In the brain, dopamine plays an important role in the regulation of reward and movement. As part of the reward pathway, dopamine is manufactured in nerve cell bodies located within the ventral tegmental area (VTA) and is released in the nucleus accumbens and the prefrontal cortex. Its motor functions are linked to a separate pathway, with cell bodies in the substantia nigra that manufacture and release dopamine into the striatum.
**Source:** Wikimedia Commons, CC BY-SA 3.0

The team hypothesized that fungal-induced PGE₂ would increase alcohol-seeking behavior, making the beverage more rewarding to the mice.
They were wrong.

Instead of showing increased interest in alcohol, mice with a C. albicans overgrowth began avoiding it. Despite being exposed to alcohol regularly, their preference shifted away from it, defying expectations. Blocking PGE₂ receptors reversed this aversion, restoring alcohol consumption.

A Lesson in Scientific Curiosity

“Our study shows how science works — our initial ideas were very wrong,” said Andrew Day, lead author and former Ph.D. student at Tufts. “This could be explained by differences in how mice respond to C. albicans compared to humans, differences in fungal strains, or we might be seeing a small snapshot of the entire story.”

More Than Just Preference

The effects weren’t limited to preference. The study also found that mice with fungal overgrowth were more sensitive to alcohol’s impact on motor coordination — essentially, they became more easily impaired. Again, this effect was linked to PGE₂ and could be reversed when its activity was blocked.

This dual finding — behavioral aversion and increased motor sensitivity — paints a broader picture of how gut microbes might influence not just our cravings but also our physical responses to substances like alcohol.

Implications for Alcohol Use Disorder

Alcohol use disorder is a deeply complex condition. It’s not simply about willpower or choice. Genetics, neurochemistry, trauma, environment, and now — possibly — the gut microbiome, all play a role.

Traditional treatments such as cognitive behavioral therapy, support groups, medications, and lifestyle changes have helped many. Yet relapse rates remain high, and not all individuals respond to these interventions. That’s why researchers are increasingly exploring the gut-brain axis as a potential new frontier.

The Tufts study aligns with recent clinical interest in fecal microbiota transplantation (FMT) as a treatment for alcohol use disorder. Preliminary human studies suggest that altering the microbial landscape of the gut can affect alcohol consumption behaviors. Fungi like C. albicans may be key players in this process.

The Power of Inflammation

The study’s focus on PGE₂ underscores the central role that inflammation may play in addiction pathways. Unlike bacterial toxins or immune cell responses, PGE₂ is a subtle but influential molecule. It can modulate pain, behavior, and now — it seems — alcohol response.

Blocking its activity reversed both the behavioral and motor effects in the study’s mice. This raises the possibility of future drug development aimed at modulating PGE₂ pathways as a treatment for alcohol dependence.

It also presents a cautionary tale. The microbiome is a delicate ecosystem, and shifts in its fungal components can have neurochemical consequences. As we continue to explore its influence, it’s crucial to understand not just which species are present, but how they interact with the host.

Where Do We Go From Here?

The connection between gut fungi and alcohol behavior is still in its early days. This study is one piece of a much larger puzzle, but it’s a compelling one. It invites further investigation into:

How C. albicans overgrowth occurs in humans with alcohol use disorder
Whether PGE₂ plays a similar role in the human brain
How fungal strains differ in their ability to affect host behavior
What treatments might modulate fungal activity or inflammatory signaling

As researchers continue to trace the fine threads between gut and brain, it becomes increasingly clear that addiction is not simply a mental health issue — it is a whole-body condition.
And sometimes, the smallest organisms may be the loudest voices in that conversation.

References

Primary Study & Journals

According to NEWS MEDICAL LIFE SCIENCES

Key Takeaways

Research has found that Candida albicans—a fungus normally resident in the gut—can influence brain dopamine signalling in ways that alter alcohol preference and reward responses.
The proposed mechanism involves gut-brain axis communication: fungal metabolites and immune signals triggered by gut Candida affect neurotransmitter production and BBB permeability.
C. albicans proliferates in the gut under high-sugar, high-alcohol diets, creating a potential positive-feedback loop between alcohol consumption and intestinal fungal overgrowth.
Antifungal treatment in preclinical mouse models reduced alcohol preference—though human clinical trials demonstrating therapeutic benefit are not yet available.
This research represents a new frontier in addiction biology, suggesting that gut microbial composition may be a modifiable factor in alcohol use disorder vulnerability and treatment.

Frequently Asked Questions

How can a gut fungus affect brain function and alcohol preference?

The gut-brain axis is a bidirectional communication network between intestinal microorganisms and the central nervous system operating through several pathways: the vagus nerve (which carries signals from gut to brain stem); immune system signalling (gut microorganisms influence systemic cytokine levels that affect brain function); the enteric nervous system (the ‘second brain’ embedded in the gut wall); and metabolite production (microbial metabolites enter the bloodstream and can cross the blood-brain barrier). Candida albicans can influence these pathways through: production of metabolites including acetaldehyde (a toxic alcohol metabolism product that can reach the brain); induction of gut inflammation that alters intestinal permeability (‘leaky gut’); and effects on gut serotonin production (90% of serotonin is produced in the gut under microbial influence).

What does the research actually show about Candida and alcohol?

Preclinical research (primarily in mouse models) has shown associations between gut Candida abundance and alcohol-related behaviours. Studies at Weill Cornell Medicine found that alcohol consumption in mice promoted gut Candida overgrowth, and that mice with higher gut Candida abundance showed altered dopamine signalling in reward-related brain regions and higher voluntary alcohol consumption. When these mice were treated with antifungal medication (specifically fluconazole), gut Candida was reduced and alcohol preference decreased. The research is compelling as a mechanistic hypothesis but has significant translational limitations—mouse models of alcohol use disorder imperfectly model human addiction, and the strength of the fungal contribution relative to other biological and psychosocial factors in human alcohol use disorder has not been established.

Does alcohol cause Candida overgrowth in the gut?

Alcohol disrupts gut microbiome balance in multiple ways that can promote Candida overgrowth. Alcohol and its metabolite acetaldehyde directly damage gut epithelial cells, increasing intestinal permeability and altering the chemical environment of the gut lumen. Alcohol consumption shifts gut bacterial communities away from Lactobacillus and Bifidobacterium species that normally compete with and suppress Candida. Alcohol also stimulates gastric acid secretion patterns that alter fungal colonisation resistance. Clinical studies of heavy alcohol drinkers consistently find higher gut Candida colonisation rates and abundance compared to non-drinkers, and alcohol cessation is associated with decreasing Candida levels. This creates a potential self-reinforcing cycle: alcohol promotes Candida overgrowth, which may increase alcohol preference, which further promotes Candida overgrowth.

Could antifungal treatment help with alcohol use disorder?

The translational evidence remains speculative, and no clinical trials of antifungal treatment for alcohol use disorder have reported positive results in humans. The preclinical evidence from mouse models is intriguing—antifungal treatment reduced alcohol preference. However, mouse models capture only narrow aspects of human alcohol dependence, which involves complex genetic, psychological, social, and neurodevelopmental factors far beyond gut mycobiome composition. Responsible interpretation is that gut Candida may be one modifiable biological factor among many contributing to alcohol use disorder vulnerability—not a primary cause or a primary therapeutic target. Targeting gut Candida through dietary modification (reducing sugar intake) and possibly probiotic or antifungal interventions might be studied as adjunctive strategies in alcohol use disorder treatment, but is not currently evidence-based clinical practice.

What lifestyle factors affect gut Candida levels?

Several modifiable lifestyle factors influence gut Candida colonisation. Diet: high refined carbohydrate and sugar intake provides fermentable substrate that promotes Candida growth; the ‘candida diet’ (eliminating sugar, refined carbohydrates, and certain fermented foods) is based on this principle, though its effectiveness in eliminating pathological Candida overgrowth is not well-established by clinical evidence. Antibiotic use: broad-spectrum antibiotics eliminate competing bacteria, allowing Candida populations to expand—’antibiotic-associated Candida overgrowth’ is a documented clinical phenomenon. Fermented foods: regular consumption of Lactobacillus-rich fermented foods appears to modestly reduce gut Candida abundance in some studies. Alcohol: as discussed, heavy alcohol use is associated with higher gut Candida. Immunosuppressive medications: reduce the immune system’s capacity to contain Candida populations.